a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2490 clinical trials
Study of Safety Tolerability and PK PD of HPG1860 in Healthy Subjects

This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HPG1860 orally administered in healthy subjects.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities

the incidence of the disease of retinal degenerations with loss of photoreceptors (related to old age or genetic) on patients' daily lives, is poorly characterize without standardized means of measurement (usually performed with functional vision or reading tasks). self-assessment by a quality of life questionnaire correlated with an assessment of …

retinopathy
gene therapy
direct observation
amblyopia
cognitive disorders
  • 0 views
  • 05 Aug, 2020
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease

coronavirus infection
pao2/fio2 ratio
chest imaging
fraction of inspired oxygen (fio2)
pao2
  • 0 views
  • 05 Aug, 2020
Healthy Test study

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax

  • 0 views
  • 30 Aug, 2020
  • 1 location
v4.7 Sprint Demo Study - TrialX  

All patients who successfully complete all 3 survey questionnaires will be eligible for a structured interview portion of the study to explore themes that will inform care model redesign.

  • 0 views
  • 14 Apr, 2022
  • 6 locations
Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers

Dietary fat plays a crucial role as a modifiable risk factor influencing both non-fasting lipaemia and vascular reactivity. Notably, the intake of dietary saturated fatty acids (SFAs) has been associated with adverse effects on blood lipid profiles, whereas increased consumption of unsaturated fatty acids (UFAs) has shown potential to improve …

Accepts healthy volunteers
  • 0 views
  • 22 Sep, 2023
  • 1 location
NoIAmNot Trial

The minimum acceptable dose for infusion is 1 x 10xE7 CART19 cells. Subjects originally treated under Stage 1 will receive a single infusion, if sufficient CART19 product remains. For patients from Stage 1 who do not have a sufficient dose remaining, subjects will be remanufactured under Stage 2 conditions and …

  • 0 views
  • 21 Feb, 2023
enrolling Trial

The minimum acceptable dose for infusion is 1 x 10xE7 CART19 cells. Subjects originally treated under Stage 1 will receive a single infusion, if sufficient CART19 product remains. For patients from Stage 1 who do not have a sufficient dose remaining, subjects will be remanufactured under Stage 2 conditions and …

  • 0 views
  • 22 Feb, 2023
COPD-ICU Multicentre Prospective Observational Register (COPD-ICU)

The minimum acceptable dose for infusion is 1 x 10xE7 CART19 cells. Subjects originally treated under Stage 1 will receive a single infusion, if sufficient CART19 product remains. For patients from Stage 1 who do not have a sufficient dose remaining, subjects will be remanufactured under Stage 2 conditions and …

  • 0 views
  • 21 Feb, 2023
second sync

The minimum acceptable dose for infusion is 1 x 10xE7 CART19 cells. Subjects originally treated under Stage 1 will receive a single infusion, if sufficient CART19 product remains. For patients from Stage 1 who do not have a sufficient dose remaining, subjects will be remanufactured under Stage 2 conditions and …

  • 0 views
  • 21 Feb, 2023